Molecular genetic and epigenetic mechanisms of primary and secondary resistance to imatinib mesylate treatment in ph chromosome positive chronic myeloid leukemia patients

Imatinib mesylate (IM) is a BCR-ABL targeted tyrosine kinase inhibitor drug used for frontline therapy in patients with chronic myeloid leukemia (CML). IM is highly effective and is considered the standard of care in CML management. Even though IM has become the gold standard frontline treatment...

Full description

Saved in:
Bibliographic Details
Main Author: Elias, Marjanu Hikmah
Format: Thesis
Language:English
Published: 2015
Subjects:
Online Access:http://eprints.usm.my/40418/1/Dr._Marjanu_Hikmah_Elias_PhD-24_pages.pdf
Tags: Add Tag
No Tags, Be the first to tag this record!